Prosecution Insights
Last updated: November 04, 2026
Application No. 18/686,600

MINERALIZED COLLAGEN MATERIAL, PREPARATION METHOD THEREFOR, AND APPLICATION THEREOF

Non-Final OA §103§112
Filed
Feb 26, 2024
Priority
Mar 29, 2022 — CN 202210319532.6 +1 more
Examiner
ABBAS, SYED JARAR
Art Unit
1674
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Shanghai Tenth People’S Hospital
OA Round
1 (Non-Final)
25%
Grant Probability
At Risk
1-2
OA Rounds
9m
Est. Remaining
25%
With Interview

Examiner Intelligence

Grants only 25% of cases
25%
Career Allowance Rate
1 granted / 4 resolved
-35.0% vs TC avg
Minimal +0% lift
Without
With
+0.0%
Interview Lift
resolved cases with interview
Typical timeline
3y 5m
Avg Prosecution
35 currently pending
Career history
43
Total Applications
across all art units

Statute-Specific Performance

§101
2.0%
-38.0% vs TC avg
§103
19.7%
-20.3% vs TC avg
§102
25.2%
-14.8% vs TC avg
§112
36.7%
-3.3% vs TC avg
Black line = Tech Center average estimate • Based on career data from 4 resolved cases

Office Action

§103 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claim 1-10 are pending. Election/Restrictions Applicant’s election without traverse of invention Group I (claim(s) 1-8 drawn to a method for preparing a mineralized collagen material) in the reply filed on 09/11/2026 is acknowledged. Claim 9 and 10 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made without traverse in the reply filed on 09/11/2026. Claims 1-8 are under examination. Information Disclosure Statement No information disclosure statement was filed. Claim Rejections - 35 USC § 112 The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 5-8 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the invention. The “~” symbol, also known as a tilde, can have various meanings such as “about”, “approximately”, or “around”. In the context of the claims, this renders the claims indefinite. To overcome the rejection, Applicant may remove the symbol and describe the meaning of the symbol in words. Clarification and/or correction is required. Claim Rejections - 35 USC § 103 The following is a quotation of 35 U.S.C. 103 which forms the basis for all obviousness rejections set forth in this Office action: A patent for a claimed invention may not be obtained, notwithstanding that the claimed invention is not identically disclosed as set forth in section 102, if the differences between the claimed invention and the prior art are such that the claimed invention as a whole would have been obvious before the effective filing date of the claimed invention to a person having ordinary skill in the art to which the claimed invention pertains. Patentability shall not be negated by the manner in which the invention was made. 8. Claim(s) 1-8 are rejected under 35 U.S.C. 103 as being obvious over Liu, et al. (US 6417166 B2, published Jul. 9, 2002) in view of Penkova, R, et al. “Stabilizing effect of glycerol on collagen type I isolated from different species.” Food Chemistry, vol. 66, no. 4, Sept. 1999, pp. 483–487, https://doi.org/10.1016/s0308-8146(99)00097-7. The instant claims are drawn to a method for preparing a mineralized collagen material, wherein comprising the steps of: dissolving type I collagen, calcium source and acid in a first solvent to obtain a first solution, in which the first solvent is glycerin or a mixed solvent of glycerin and water; dissolving alkali and phosphorus source in a second solvent to obtain a second solution, in which the second solvent is glycerin, water or a mixed solvent of glycerin and water; adding the second solution to the first solution at a temperature of <45°C, then mixing them to obtain a third solution, in which pH of the third solution is >7; and, immersing the third solution in a deionized water solvent or an ethanol solvent to remove impurities to obtain a mineralized collagen gel. Liu teaches a method of making mineralized collagen. The starting collagen, including type I collagen (Example 1, column 8), may be natural, recombinant, solid, a solution or a slurry (column 4, lines 54-62). Liu teaches solid collagen is dispersed in an acidic solution such as acetic acid to give homogenous gel-type slurry (column 4, line 64 and column 8, lines 38 to 42). A soluble calcium salt such as calcium chloride or nitrate may be dissolved or otherwise combined directly into the collagen slurry (column 5, lines 1-7 and column 7, lines 5-15). Liu further teaches the phosphate component is then dissolved separately in a liquid medium, preferably water (column 5, lines 8-20). Liu further teach an alkali such as sodium, potassium or ammonium hydroxide may be added to the phosphate containing solution before it is combined (column 5, lines 44-48). The phosphate solution is added to the stirred collagen slurry, below about 40 C and at pH of at least about 7, preferable at least 9 (column 5, lines 8-20 and 38-44). Liu further teach the product is washed several times with pure water until free of soluble impurities then re-slurried in water (column 5, line 58, column 6, line 3, column 8, line 61-67 and claim 14(f). Liu teaches that mineralized collaged has been prepared by freeze-drying to form a sponge structure (column 2, lines 9-14) as recited in instant claim 2. Liu teaches letting the slurry stand unstirred until precipitation is complete, about 1 hour in Example 1, with the mixture kept below about 40 C (column 5, lines 33-41; column 8, lines 56-58). Room temperature falls within the range as recited in instant claim 3. Liu further teaches vigorous mixing or stirring, in a blender in the examples (column 5, lines 30-33; example 1) as recited in instant claim 4. Liu teaches collagen concentration of about 0.1-5% or about 1-50mg/ml (column 4, line 62 to column 5, line 1. Collagen is animal derived or recombinant (col. 4, lines 54-56). The calcium sources are calcium chloride and calcium nitrate (col 7, lines 5-15) and the acid is acetic acid (example 1). Examples 1 calcium chloride is about 0.5 M in its 30 ml solution with less than 5 mol/L. This recites the limitation of instant claim 6. Liu teaches water as the second solvent (0% glycerin, within 0-100%). It teaches NaOH, KOH, and NH4OH as the alkali (col 5, lines 43-48, col 7, lines 32-36) and alkali metal and ammonium phosphorus source (col 7, lines 16-27). Examples 1’s phosphate is about 0.5 M, with less than 3 mol/L. This recites the limitation of instant claim 7. Liu teaches the Ca:P ratio is about 1-2, preferably 1.67 (col 6, lines 26-30). This meets the limitation of instant claim 8. Liu does not teach a first solvent of glycerin or glycerin and water. However, Penkova investigated the stabilizing effect of glycerol on type I collagens from rat tail tendon, calf skin, human placenta and sheep skin at elevated temperatures and in urea (see page 483). Penkova tech that in the presence of glycerol, the collagen molecule was stabilized, not only by heating but also by the action of urea. Figures 1-4 demonstrate the different type I collagens in the presence of glycerol with increased temperature and demonstrated similar stability. Liu states that “any suitable liquid medium may be used” (column 7, lines 28-31). It would have been prima facie obvious before the effective filing date of the claimed invention to modify the method of preparing a mineralized collagen taught by Liu et al. to use glycerin as the first solvent because Penkova demonstrated increased stability of type I collagen in the presence of glycerin with increasing temperatures. One of ordinary skill in the art would have been motivated to use glycerin as the solvent when preparing a mineralized collagen material for the benefit of increased collagen stability, and with a reasonable expectation of success. Additionally, KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727, 1741 (2007), discloses that if a technique has been used to improve one method, and a person of ordinary skill would recognize that it would be used in similar methods in the same way, using the technique is obvious unless its application is beyond that person’s skill. KSR International Co. v. Teleflex Inc., 127 S. Ct. 1727, 1741 (2007) also discloses that “The combination of familiar element according to known methods is likely to be obvious when it does no more than yield predictable results”. Thus, the combination of prior art references to arrive at the claimed invention provided a prima facie case of obviousness, absent evidence to the contrary. Regarding the limitation in instant claim 5 that recites “wherein a dripping speed of adding the second solution to the first solution is 0.1~10000 mL/min”, Liu teaches the rapidity of adding the calcium component or the phosphate component to the collage slurry is not critical and the two solution may be added to the collagen slurry slowly or quickly (column 5, lines 21-33). The dripping speed can clearly be a result effective parameter that a person having ordinary skill in the art would routinely optimize. Optimization of parameters is a routine practice that would be obvious for a person of ordinary skill in the art to employ. It would have been customary for an artisan of ordinary skill to determine the optimal amount of each ingredient, i.e., the dosage and dosing regimen, needed to achieve the desired results. The principle of law states from MPEP §§ 2144.05: "The normal desire of scientists or artisans to improve upon what is already generally known provides the motivation to determine where in a disclosed set of percentage ranges is the optimum combination of percentages," (see In re Peterson, 315 F.3d at 1330, 65 USPQ2d at 1382). Generally, differences in concentration or temperature will not support the patentability of subject matter encompassed by the prior art unless there is evidence indicating such concentration or temperature is critical. "[W]here the general conditions of a claim are disclosed in the prior art, it is not inventive to discover the optimum or workable ranges by routine experimentation," (See In re Aller, 220 F.2d 454, 456, 105 USPQ 233, 235 (CCPA 1955)). Conclusion 9. No claims are allowed. 10. Any inquiry concerning this communication or earlier communications from the examiner should be directed to Syed J Abbas whose telephone number is (571)272-0015. The examiner can normally be reached M-Th, 9:00AM-4:00PM. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Vanessa Ford can be reached at 571-272-0857. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /SYED J ABBAS/Examiner, Art Unit 1674 /VANESSA L. FORD/Supervisory Patent Examiner, Art Unit 1674
Read full office action

Prosecution Timeline

Feb 26, 2024
Application Filed
Oct 20, 2026
Non-Final Rejection mailed — §103, §112 (current)

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
25%
Grant Probability
25%
With Interview (+0.0%)
3y 5m (~9m remaining)
Median Time to Grant
Low
PTA Risk
Based on 4 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month